Sano Genetics has partnered with GenePlaza to link individuals who have used direct-to-consumer (DTC) genetic tests with clinical trials and other research programs, the companies said recently.

UK-based Sano, which recently raised ￡500,000 ($622,231) in seed funding, has developed a data-sharing platform that enables people to submit their medical and genetic data in order to be matched with research studies that could benefit from the information in exchange for a personalized health report. Belgium-based GenePlaza markets a portfolio of web-based applications that customers can use to interpret data from DTC genetic tests.

Under the terms of the deal, GenePlaza will offer an app through which its customers can review and opt into research projects through Sano's platform. Users can join projects run by non-profit organizations including studies into autism, stomach ulcers, and autoimmune conditions by researchers at the University of Cambridge, the University of Liverpool, and Imperial College London, as well as studies run by and for-profit companies including clinical trials in atopic dermatitis and pharmacogenomics and R&D projects for new treatments of rare and chronic diseases.

Additional terms of the partnership were not disclosed.